<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459133</url>
  </required_header>
  <id_info>
    <org_study_id>IND110021</org_study_id>
    <nct_id>NCT01459133</nct_id>
  </id_info>
  <brief_title>Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System</brief_title>
  <official_title>Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Orange County Endocrinology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>South Orange County Endocrinology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this program is to allow patients with diabetes and with specific medical
      needs which require them to use this investigational inhaled insulin product in order to
      adequately manage their diabetes. Treatment use of this investigational product is only
      anticipated when exceptional need is identified by a treating physician on a per patient case
      by case review.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program is for patients who have been diagnosed with diabetes mellitus and has
      established a need for treatment with this investigational product documented by a health
      care professional. The treating doctor, or a member of his/her staff, will discuss the
      specific requirements for participation with the subject.

      INVESTIGATIONAL PRODUCT DESCRIPTION:

      Technosphere® Insulin Inhalation System includes Technosphere® Insulin Inhalation Powder and
      inhaler. The Inhalation Powder comes in 10 unit and 20 unit cartridges.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to register Treatment IND with the US Food And Drug Administration's new process of
    establishing TLS encryption for email correspondence.
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Inhaled Insulin versus Subcutaneous Insulin in a patient who receives inadequate response from subcutaneous alone.</measure>
    <time_frame>12-months</time_frame>
    <description>Evaluate fasting plasma glucose and hemoglobin a1c</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Technosphere® Insulin Inhalation System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Site, Single Subject use of Technosphere® Insulin Inhalation System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere® Insulin Inhalation System</intervention_name>
    <description>Single Site, Single Subject use of Technosphere® Insulin Inhalation System</description>
    <arm_group_label>Technosphere® Insulin Inhalation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Documented diagnosis with diabetes mellitus and have established a need for treatment with
        the investigational product.

        Local Ethics Committee approval has been documented, as needed. Patient has signed the
        Informed Consent Form for participation. Patient has successfully completed training on the
        Technosphere Insulin Inhalation System.

        Exclusion Criteria:

        Allergy to Insulin. Smoking in the previous 6-months. History of asthma or COPD or any
        other significant pulmonary disease, or exposure to pulmonary toxins.

        Clinical significant abnormality in screening laboratory tests. Positive pregnancy test or
        the intention to become pregnant. Women of childbearing age without appropriate method of
        contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Orange County Endocrinology</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>investigational</keyword>
  <keyword>inhaled insulin product</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

